All In Biotech

Free tool

FAERS Monitor: Rozlytrek

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212726 or its brand name (Rozlytrek, Entrectinib). Reports on generic versions are filed under their own applications.

Reports

1,691

Serious

1,103

65% of reports

Hospitalization

356

Death reported

275

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use173
  • dizziness157
  • death135
  • disease progression119
  • taste disorder74
  • no adverse event72
  • drug ineffective69
  • constipation68
  • blood creatinine increased66
  • fatigue64
  • diarrhoea63
  • renal impairment62
  • nausea59
  • weight increased54
  • cardiac failure50

Reports by year received

View as table
YearReports
20171
20181
201932
2020125
2021233
2022288
2023263
2024467
2025172
2026109

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,468 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
taste disorderSignal7445.536.43,170
blood creatinine increasedSignal6612.69.9694
disease progressionSignal11912.510.51,256
renal impairmentSignal629.27.2446
cardiac failureSignal507.85.9288
no adverse eventSignal724.93.9224
dizzinessSignal1573.93.4346
constipationSignal683.93.1144
weight increasedSignal543.02.371
off label useSignal1732.52.1155
death1351.91.764
diarrhoea631.21.02
fatigue641.00.80
nausea590.90.70
drug ineffective690.70.513

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.